Abstract
New pyrazolo[3,4-d]pyrimidines were synthesized and found to inhibit Src phosphorylation in a cell-free assay. Some of them significantly reduced the growth of human osteogenic sarcoma (SaOS-2) cells. The best compound, in terms of inhibitory properties toward both Src and SaOS-2 cells, was further investigated and found to reduce bone resorption when used to treat mouse osteoclasts, without interfering with normal osteoblast growth. Moreover, its metabolic stability prompted its study on a human SaOS-2 xenograft tumor model in nude mice, where the compound reduced significantly both the volume and weight of the tumor. These experimental findings make the new compound an interesting hit in the field of bone-related diseases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / pathology
-
Bone Resorption / prevention & control
-
Cell Line, Tumor
-
Cell Proliferation / drug effects*
-
Cells, Cultured
-
Drug Screening Assays, Antitumor
-
Humans
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Osteoblasts / drug effects
-
Osteoclasts / drug effects
-
Osteosarcoma / drug therapy*
-
Osteosarcoma / pathology
-
Phosphorylation
-
Pyrazoles / chemical synthesis*
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology
-
Structure-Activity Relationship
-
Transplantation, Heterologous
-
src-Family Kinases / antagonists & inhibitors
-
src-Family Kinases / metabolism
Substances
-
Pyrazoles
-
Pyrimidines
-
src-Family Kinases